doi: 10.1093/ajcn/80.1.101
However, the American Gastroenterological Association (AGA) has recently updated its clinical practice guidelines, advising against a one-size-fits-all approach to stopping GLP-1 receptor agonists (like Ozempic and Trulicity) before endoscopic procedures
Diabetes, Obesity and Metabolism, 23(2), 581-588
Candidates should be thoroughly evaluated to ensure that Semaglutide GLP-1 is safe and effective for their needs
Nausea, vomiting, diarrhea, and constipation are the most common side effects, especially during the first weeks of treatment or when doses increase
Switching back follows a similar process: finish your last tirzepatide dose and start semaglutide on your next scheduled injection day